Ragon Institute of Mass General, MIT, and Harvard
Dana Thornlow Lamson is a Postdoctoral Research Fellow at the Ragon Institute of MGH, MIT, and Harvard since November 2019, focusing on engineering influenza immunogens and understanding antibody responses, with expertise in structure-guided immunogen design and various protein and antibody techniques. Prior to this role, Dana completed a Ph.D. in Chemical and Biomolecular Engineering at Cornell University, where thesis work centered on antibody bioconjugates and siRNA delivery systems, alongside significant experience in protein and nucleic acid bioconjugation. Previous experience includes a Research Assistant position at the University of Massachusetts Amherst, developing a selection method for isolating motile Salmonella typhimurium populations for cancer therapy, and serving as a Resident Assistant, planning community events for students. Dana holds a Bachelor's Degree in Chemical Engineering from the University of Massachusetts Amherst.
This person is not in the org chart
Ragon Institute of Mass General, MIT, and Harvard
1 followers
The Ragon Institute was established in 2009 with a dual mission: to contribute to the accelerated discovery of an HIV/AIDS vaccine and subsequently establish itself as a world leader in the collaborative study of immunology. Founded with a commitment of $100 million from Phillip T. (Terry) and Susan M. Ragon, and with an additional $200 million gift to endow the Institute announced on April 26, 2019, the Institute is structured and positioned to significantly contribute to a global effort to successfully develop an HIV/AIDS vaccine by: • Creating non-traditional partnerships among experts with different but complementary backgrounds; • Providing a means for rapidly funding promising studies; • Integrating key facets of vaccine development efforts that have tended to follow separate tracks; • Providing a substantial pool of accessible, flexible funding that lowers the threshold for scientists to pursue risky, unconventional avenues of study that are unlikely to attract funding from traditional sources. Such funding encourages innovation, compresses the time it takes to conduct bench-to-bedside research and attracts new minds to the field. The Ragon Institute creates a singular opportunity and environment to engage scientists, engineers and clinicians in challenging research for which there is no greater benefit – saving lives and curing the ill.